Ameliorative effect of Vitamin D on CPF toxicity by evaluation of Wistar rat liver enzymes and kidney biomarkers
نویسندگان
1 DSc., Associate Professor of Department of Neurology, Vice Rektor of Bukhara State Medical Institute, Bukhara, Uzbekistan
2 Head of the Department of Pediatrics-2, Fergana Medical Institute of Public Health, Fergana, Uzbekistan
3 Mamun University, Khiva, Uzbekistan
4 Doctor of Philosophy (PhD) in Pedagogical Sciences, Associate Professor, Head of the Department of
5 Professor, Pharmaceuticals and Chemistry, Faculty of Medicine, Alfraganus University, Tashkent, Uzbekistan
6 Kimyo International University in Tashkent Shota Rustaveli Street 156, 100121, Тashkent, Uzbekistan
7 Assistant of the Neurology Department, Faculty of Postgraduate Education, Samarkand State Medical University, Uzbekistan
8 Oncologist, Pediatric Oncosurgery, Interventional Oncologist; Scientific Researcher in the Department of
9 Director, Scientific Research Institute of Cereals and Leguminous Crops, Navoi Scientific Experimental Station, Navoiy, Uzbekistan; Scientific Researcher, Navoi State University of Mining and Technologies, Navoiy, Uzbekistan
doi
10.22124/cjes.2025.8571چکیده
Chlorpyrifos (CPF) is a hepatotoxic agent that adversely affects multiple organ systems. This study investigated how Vitamin D mitigates liver and kidney damage caused by CPF exposure. Fifteen Wistar rats were divided into three groups: CPF (3 mg/kg BW), Control (PBS), and Vitamin D (1 µg/g BW). Serum total antioxidant capacity (TAC) and total oxidative stress (TOS) were measured, along with enzyme levels, to assess liver and kidney function. CPF treatment resulted in elevated biomarkers indicating organ damage, while Vitamin D treatment decreased these biomarkers and enzyme levels. The protective effects of vitamin D may stem from its antioxidant and anti-inflammatory properties. Notably, blood urea nitrogen (BUN), serum glutamic-oxaloacetic transaminase (SGOT), serum glutamic-pyruvic transaminase (SGPT), and alkaline phosphatase (ALP) levels were significantly lower in the Vitamin D group than in the CPF group. TAC levels in the treated group were lower than in controls, indicating increased oxidative stress, while TOS levels rose significantly, suggesting oxidative damage. These results highlight CPF's role in renal and hepatic injuries and emphasize the importance of enzyme analysis in assessing hepatotoxicity potentially influenced by Vitamin D. The research concludes that Vitamin D supplementation significantly mitigates liver and kidney damage caused by CPF exposure. This is evidenced by lower levels of liver enzymes and kidney biomarkers in the Vitamin D group compared to the CPF group, indicating a protective role against organ damage.
